ライフサイエンスコーパス: adverse outcome

1 to identify independent risk factors for an adverse outcome.

2 function leading to atrial fibrillation with adverse outcome.

3 identify asymptomatic patients with OMR and adverse outcome.

4 he opportunity to detect patients at risk of adverse outcome.

5 aque/thrombus protrusion was associated with adverse outcome.

6 ic medical centers to validate predictors of adverse outcome.

7 gitation were also significant predictors of adverse outcome.

8 ultiple attributes was a strong predictor of adverse outcome.

9 ureus bacteremia is often associated with an adverse outcome.

10 ne expression change that is associated with adverse outcome.

11 g the first year of therapy, associated with adverse outcome.

12 ing a molecular initiating event (MIE) to an adverse outcome.

13 to minimize risk of treatment failure and/or adverse outcomes.

14 py-related myeloid neoplasm (TMN), and other adverse outcomes.

15 ciated with significant short- and long-term adverse outcomes.

16 etween maximizing graft survival and serious adverse outcomes.

17 ciation with in-hospital, 30-day, and 1-year adverse outcomes.

18 ronic kidney disease and are associated with adverse outcomes.

19 ociated with inflammation, hypertension, and adverse outcomes.

20 t characteristics associated with short-term adverse outcomes.

21 which are also prospectively associated with adverse outcomes.

22 eart failure (HF) severity and predictors of adverse outcomes.

23 =0.90) or in secondary maternal or perinatal adverse outcomes.

24 ndergoing noncardiac surgery are at risk for adverse outcomes.

25 cause highly persistent infections and later adverse outcomes.

26 ly improves the reclassification of risk for adverse outcomes.

27 tracerebral haemorrhage (ICH) and associated adverse outcomes.

28 n patients older than 65 years, and presages adverse outcomes.

29 se (CAD) pathogenesis and is associated with adverse outcomes.

30 essential to understand its contribution to adverse outcomes.

31 llowed interventions that may have prevented adverse outcomes.

32 tage and correlate with disease severity and adverse outcomes.

33 ransplantation is common and associated with adverse outcomes.

34 nical manifestation, and are associated with adverse outcomes.

35 h-risk patients and anticipate postoperative adverse outcomes.

36 ing pregnancy might be associated with fetal adverse outcomes.

37 FpEF who were followed up longitudinally for adverse outcomes.

38 that could potentially have ZIKV-associated adverse outcomes.

39 s associated with a broad spectrum of severe adverse outcomes.

40 that prolonged TTC would be associated with adverse outcomes.

41 fied a subset of patients at higher risk for adverse outcomes.

42 men were reviewed, and all cases resulted in adverse outcomes.

43 fferentially associated with greater risk of adverse outcomes.

44 and/or sedative therapies and contribute to adverse outcomes.

45 y individuals at greatest susceptibility for adverse outcomes.

46 es in identifying patients at higher risk of adverse outcomes.

47 study may not have been able to detect rare adverse outcomes.

48 eria combinations that predicted the risk of adverse outcomes.

49 y disease etiology and improve prediction of adverse outcomes.

50 rom pretransplant levels are associated with adverse outcomes.

51 odified the effect of a positive troponin on adverse outcomes.

52 on, and content, potentially contributing to adverse outcomes.

53 increased risk for cardiovascular and other adverse outcomes.

54 some studies have shown an association with adverse outcomes.

55 natremia, without evidence of an increase in adverse outcomes.

56 associated with significantly lower risk of adverse outcomes.

57 tential biomarker for the detection of these adverse outcomes.

58 championed therapeutics that mitigate these adverse outcomes.

59 g pregnancy is generally not associated with adverse outcomes.

60 roponin T (hs-cTnT) level is associated with adverse outcomes.

61 gy to stratify patients at increased risk of adverse outcomes.

62 ing pregnancy has been associated with other adverse outcomes.

63 ncreased risk of complicated appendicitis or adverse outcomes.

64 length of stay; and several other important adverse outcomes.

65 s were not detected to increase the risk for adverse outcomes.

66 uces gene expression changes associated with adverse outcomes.

67 odemographic and CSE factors associated with adverse outcomes.

68 weight </=25th or >/=85th centile may reduce adverse outcomes.

69 eight-related comorbidities, and all related adverse outcomes.

70 depressant exposure has been associated with adverse outcomes.

71 rceptions of quality or of the likelihood of adverse outcomes.

72 nally immunosuppressive, and associated with adverse outcomes.

73 with pChk2, was an independent predictor of adverse outcomes (10-year survival: pATR: HR 2.74, 95% C

74 Nearly 80% of adverse outcomes (274 000) occurred in women who receive

75 dependency by examining short- and long-term adverse outcomes according to DM status and therapy in t

76 We found a wide range of risk for adverse outcomes after AMI in diabetic patients.

77 o prevent acute kidney injury and associated adverse outcomes after angiography without definitive ev

78 Gait speed is an independent predictor of adverse outcomes after cardiac surgery, with each 0.1-m/

79 f a validated risk-standardization model for adverse outcomes after congenital cardiac catheterizatio

80 etes mellitus (DM) have an increased risk of adverse outcomes after coronary artery bypass grafting (

81 in these patients confers a greater risk of adverse outcomes after even minor stressors.

82 We assessed adverse outcomes after first, single mesh procedures and

83 e infected with ZIKV (55% of pregnancies had adverse outcomes after maternal infection in the first t

84 e claims data, the study assessed risks of 3 adverse outcomes after receipt of cataract surgery for b

85 independent risk factor for death and other adverse outcomes after trauma and compared two common in

86 n during 2013-14 influenza season attenuated adverse outcome among adults that were hospitalized with

87 We investigated the risks of adverse outcomes among 5-year survivors of WT, in partic

88 longed storage does not increase the risk of adverse outcomes among patients, although most of these

89 days from surgery, there was no evidence of adverse outcomes among those with TTC of 31 to 60 or 60

90 verse outcome pathways to identify potential adverse outcomes and biomarkers for use in subsequent mo

91 Frailty has been associated with adverse outcomes and describes a status of muscle weakne

92 ad mild symptoms, many were at high risk for adverse outcomes and obtained a large absolute benefit f

93 essive clinicopathologic characteristics and adverse outcomes and show that A3B expression is highly

94 the relationship between hypoalbuminemia and adverse outcomes and to confirm whether hypoalbuminemia

95 ortality, morbidity (any of several distinct adverse outcomes), and surgical site infection (SSI).

96 risk of preterm birth or composite neonatal adverse outcomes, and had no long-term benefit or harm o

97 SuPAR is independently predictive of adverse outcomes, and its addition to a 3-BRS comprising

98 long-term opioid use with functional status, adverse outcomes, and mortality among patients with poly

99 tient-reported functional status, documented adverse outcomes, and mortality were compared between pa

100 long-term opioid use with functional status, adverse outcomes, and mortality.

101 ombining chemical exposures linked to common adverse outcomes, and should be considered in future exp

102 ) regulatory network as a major predictor of adverse outcomes, and we found that expression of favora

103 s) describe biological mechanisms leading to adverse outcomes (AOs) by assembling causal pathways wit

104 For patients with breast cancer, adverse outcomes are associated with delaying initiation

105 of racial differences in AF and its related adverse outcomes are essential to identify and mitigate

106 Interventions to decrease these adverse outcomes are needed to maximize the overall effe

107 y; however, race/ethnicity-specific risks of adverse outcomes are not well understood.

108 inical animal testing often fails to predict adverse outcomes arising from sequential, multi-organ me

109 Other adverse outcomes, as well as the proportions of relapse,

110 The adverse outcomes associated with atrial fibrillation (AF

111 Fetal thrombosis may contribute to the adverse outcomes associated with household air pollution

112 he initially prescribed antibiotics, and the adverse outcome associations (subsequent hospital admiss

113 y, renal function was a major determinant of adverse outcomes at 1 year, and even mild or moderate re

114 harm and violent offending, respectively, as adverse outcomes at ages 15-35 years.

115 ations between maternal phthalate levels and adverse outcomes at birth and in the health of the child

116 premutation in the general community and the adverse outcomes-at both individual and systems levels-a

117 We found no differences in adverse outcomes between the groups (77 [21%] of 360 pat

118 issue hypoxia are common and associated with adverse outcomes but are not influenced by protocol-base

119 us (DM) increases tuberculosis (TB) risk and adverse outcomes but the pathological interactions betwe

120 tic shock, AKI is common and associated with adverse outcomes, but it is not influenced by protocoliz

121 rease the risk for major pregnancy and birth adverse outcomes, but little is known about possible adv

122 ity, women were more likely than men to have adverse outcomes, but the magnitude of the sex differenc

123 targeted temperature management and mitigate adverse outcomes by appropriate medication selection, do

124 Adverse outcomes categorized as partial and total graft

125 associated with a higher incidence of 1-year adverse outcomes compared with absence of PAD.

126 (MIDP) and identify actual risk factors for adverse outcomes compared with open distal pancreatectom

127 en enriched for all additional subjects with adverse outcomes (death, dialysis-dependent kidney failu

128 e in the volume-outcome model, risk-adjusted adverse outcomes declined, including mortality (3.57% to

129 The primary endpoint was 30-day adverse outcome defined as PE- or bleeding-related morta

130 nts to determine neurological outcomes, with adverse outcome defined as presence of one or more of ep

131 nt groups, which had no elevated risk for an adverse outcome despite their allocation to the milder f

132 metabolic equivalents of task hours/week and adverse outcomes during a median follow-up of 3.7 years

133 gh platelet reactivity and a greater rate of adverse outcomes during long-term follow-up.

134 hich pregnancies are no longer at risk of an adverse outcome (e.g., gestational time after 37 weeks i

135 ttle is known about the persistence of these adverse outcomes, especially relative to predeployment s

136 ng antigen, although the disease may show an adverse outcome even after avoidance of exposure to the

137 different between those with and without an adverse outcome, even when stratified by AC severity (mo

138 ury is believed to be a major determinant of adverse outcomes following traumatic brain injury (TBI).

139 nt to an association between dehydration and adverse outcomes for children with HUS.

140 d chronic hypertension) heighten the risk of adverse outcomes for mother and child if the woman becom

141 We investigated adverse outcomes for people with acute rheumatic fever (

142 nfection during pregnancy is associated with adverse outcomes for the fetus, including postnatal cogn

143 regnancy maternal obesity is associated with adverse outcomes for the offspring, including increased

144 f cardiac conditions with very high risk for adverse outcomes from IE.

145 l, and virologic data, as well as reports of adverse outcomes, from sequential participants in HCV-TA

146 ve value of sarcopenia at SICU admission for adverse outcome has not been defined.

147 iation among galectin-3, renal function, and adverse outcomes has not been described.

148 longitudinal changes in mGFR versus eGFR and adverse outcomes have not been examined.

149 g for all other variables, risk factors, and adverse outcomes, having surgery in Canada increased the

150 truction, was associated with this composite adverse outcome (hazard ratio, 5.89; 95% confidence inte

151 4+ cell count (<Q1) had the greatest risk of adverse outcomes (hazard ratio =3.5; 95% confidence inte

152 Moreover, we successfully elicited the BMP2 adverse outcomes (i.e. adipogenesis and inflammation) in

153 -adjusted inpatient and 90-day postdischarge adverse outcomes identifies considerable opportunity for

154 -adjusted inpatient and 90-day postdischarge adverse outcomes identifies considerable opportunity for

155 t immunization can protect the fetus against adverse outcomes if the mother is exposed to influenza.

156 ined with BRAF/NRAS mutations correlate with adverse outcome in adult melanoma.

157 The association between hyperlactatemia and adverse outcome in patients admitted to ICUs following g

158 S and LAVI are independently associated with adverse outcome in patients with hypertrophic cardiomyop

159 m explaining the relationship between ID and adverse outcome in RTRs.

160 taneous adipose tissue ratio, contributes to adverse outcome in sepsis patients perhaps because of a

161 sts and is a potentially reversible cause of adverse outcome in this disease.

162 ystolic HF, determine their association with adverse outcomes in a clinical trial of HF, and evaluate

163 mg/dL are independent prognostic factors for adverse outcomes in AC.

164 usly identified 2 admission risk factors for adverse outcomes in AC: total bilirubin level greater th

165 To identify determinants of adverse outcomes in acute retinal necrosis (ARN), presen

166 ographic measures of PH) are associated with adverse outcomes in CKD.

167 and predict exacerbations as well as predict adverse outcomes in critical care.

168 ing novel biomarker of AKI, death, and other adverse outcomes in critically ill patients.

169 A) size is an established marker of risk for adverse outcomes in heart failure with preserved ejectio

170 in (hsCRP), and D-dimer levels are linked to adverse outcomes in human immunodeficiency virus (HIV) i

171 s, a marker of monocyte activation, predicts adverse outcomes in human immunodeficiency virus (HIV)-i

172 nit in Pakistan to identify risk and prevent adverse outcomes in living related kidney donors.

173 d functions and canonical pathways predicted adverse outcomes in nervous and cardiovascular systems,

174 regnancy has previously been associated with adverse outcomes in offspring, but to our knowledge, the

175 ignificant trend suggesting a higher risk of adverse outcomes in older (>80) and symptomatic patients

176 ction coupling and may be exemplary of their adverse outcomes in other muscle types.

177 that variation for long-term opioid use and adverse outcomes in patients are unknown.

178 Immobilisation predicts adverse outcomes in patients in the surgical intensive c

179 haracterize the relationship between age and adverse outcomes in patients undergoing cardiac surgery

180 (PC) numbers, is an independent predictor of adverse outcomes in patients with cardiovascular disease

181 rosine kinase-1 (sFlt-1) are associated with adverse outcomes in patients with HF.

182 te that SMR, even when mild, correlates with adverse outcomes in patients with ischemic or idiopathic

183 gical early Q waves (QW) are associated with adverse outcomes in patients with ST-segment-elevation m

184 l function before pregnancy, associated with adverse outcomes in pregnancy.

185 thesia and to identify the factors linked to adverse outcomes in pregnant women exposed to anaesthesi

186 for mortality, and RA size is prognostic of adverse outcomes in pulmonary hypertension (PH).

187 ) and cardiac troponin I are associated with adverse outcomes in stable kidney transplant recipients.

188 levated levels of sFlt-1 are associated with adverse outcomes in stable patients with HF.

189 rity of hemolytic uremic syndrome (HUS), and adverse outcomes in STEC-infected individuals.

190 its association with in-stent restenosis and adverse outcomes in the ACT-1 trial (Carotid Angioplasty

191 iations were nonlinear with a higher risk of adverse outcomes in the first 100 cases.

192 patient characteristics when comparing major adverse outcomes in the NCDR's (National Cardiovascular

193 es and extracellular changes predisposing to adverse outcomes in this population.

194 ores (ie, as bad) as the maximum risk of all adverse outcomes including a 100% risk of dying before g

195 al growth restriction can lead to a range of adverse outcomes including fetal or neonatal death, neur

196 nnabis use after onset of psychosis predicts adverse outcome, including higher relapse rates, longer

197 ath (<28 days from delivery), and any severe adverse outcome, including very preterm birth (<32 weeks

198 Four women had adverse outcomes, including 2 deaths and 2 women who rem

199 ease during pregnancy may be associated with adverse outcomes, including a lower-than-normal IQ in of

200 onship between low nurse staffing levels and adverse outcomes, including higher mortality rates.

201 ated by maternal obesity are associated with adverse outcomes, including increased risk of gestationa

202 We calculated hazard ratios for 1-year adverse outcomes, including mortality, readmission, and

203 iliximab, rATG associates with lower risk of adverse outcomes, including mortality.

204 t, delirium only significantly increased all adverse outcomes, including prolonged LOS (RR, 1.9; 95%

205 ed to negative health-related behaviours and adverse outcomes, including psychological and developmen

206 associated with increased risk of composite adverse outcome independently of other risk factors.

207 low hemoglobin concentrations, the link with adverse outcomes is more evident when hemoglobin concent

208 ) type, a molecular subtype characterized by adverse outcome, is constitutive activation of the trans

209 eart associated with cardiac dysfunction and adverse outcomes likely mediated by interactions with th

210 rstanding of the mechanisms underlying these adverse outcomes limits our ability to modify present su

211 nt period and its potential association with adverse outcome may reflect greater evolutionary capacit

212 n-Barre syndrome, and 3 of 4 pregnancies had adverse outcomes (microcephaly, major fetal neurologic a

213 risk categories for both fatal and non-fatal adverse outcomes (NRI -0.027 [95% CI -0.039, -0.016], p

214 micro-RNAs, significantly contribute to the adverse outcome of atherosclerosis, myocardial infarctio

215 ry stent thrombosis (ST), which is a serious adverse outcome of peripheral artery interventions.

216 Admission hyperglycemia is associated with adverse outcome of sepsis irrespective of the presence o

217 d it could contribute to the pathogenesis of adverse outcomes of aging, like cardiovascular disease a

218 characterization and predictive validity for adverse outcomes of aging.

219 rs are serious, avoidable, costly and common adverse outcomes of healthcare.

220 To evaluate patterns and adverse outcomes of off-label use of TAVR in US clinical

221 n early pregnancy are likely to outweigh the adverse outcomes of partially treated malaria, which can

222 alculated adjusted relative risks (ARRs) for adverse outcomes of pregnancy according to endoscopy sta

223 characterize the clinical manifestations and adverse outcomes of Zika virus disease among travelers i

224 characterize the clinical manifestations and adverse outcomes of Zika virus disease among travelers i

225 ent through biological key events toward the adverse outcome on algae growth inhibition, might discri

226 fy the association between TBI and specified adverse outcomes on the individual level.

227 from their 15th birthday until occurrence of adverse outcome or December 31, 2012, whichever came fir

228 oup differences in the incidence of neonatal adverse outcomes or other adverse events.

229 jects) with severity score, ZIKV-RNA load or adverse outcomes (P = .667; OR: 0.78; 95% CI: 0.255-2.39

230 ty and viral load (P = .994); viral load and adverse outcomes (P = .667; OR: 1.02; 95% CI: 0.922-1.13

231 ERT promoter mutations alone did not predict adverse outcomes (P = 0.50), but the presence of TERT pr

232 sports participation may be associated with adverse outcomes, particularly at the elite level.

233 This review describes the EDSP's use of adverse outcome pathway (AOP) and toxicity pathway frame

234 ry companion in the exposure sciences to the adverse outcome pathway (AOP) concept in the toxicologic

235 The Adverse Outcome Pathway (AOP) framework represents a val

236 s is a greater understanding of the relevant adverse outcome pathway (AOP).

237 A quantitative adverse outcome pathway (qAOP) consists of one or more b

238 ovide information for the construction of an Adverse Outcome Pathway which could be useful in Ecologi

239 Adverse outcome pathways (AOPs) describe biological mech

240 The concept of adverse outcome pathways (AOPs) emerged as a comprehensi

241 Adverse outcome pathways (AOPs) link adverse effects in

242 bition, might discriminate between different adverse outcome pathways (AOPs).

243 ch identifies initiating events for distinct adverse outcome pathways and novel roles for individual

244 contribute toward more completely describing adverse outcome pathways associated with activation of t

245 Here we show how a systematic assessment of adverse outcome pathways based on ecologically relevant

246 ctrum, potentially valuable for establishing adverse outcome pathways of chemicals in environmental r

247 rom the EAR analysis were linked to discrete adverse outcome pathways to identify potential adverse o

248 ages between aggregate exposure pathways and adverse outcome pathways, completing the source to outco

249 oughput in vitro chemical screening based on adverse outcome pathways.

250 (MDD) and anxiety disorders over time, with adverse outcomes predicted by complex interactions among

251 AF was associated with the greatest risk of adverse outcomes: primary endpoint (HR: 2.21; 95% CI: 1.

252 ICD LF has a broad range of adverse outcomes, ranging from intermittent inappropriat

253 patients from 1570 hospitals had an overall adverse outcome rate of 20.7%; 48 hospitals had outcomes

254 patients from 1570 hospitals had an overall adverse outcome rate of 20.7%; 48 hospitals had outcomes

255 e used to compute z scores and risk-adjusted adverse outcome rates for all hospitals in the database

256 e used to compute z scores and risk-adjusted adverse outcome rates for all hospitals in the database

257 ut risk factors for admission to the ICU and adverse outcomes remain poorly defined.

258 ake a greater share of the overall burden of adverse outcomes, requiring strategic investments to add

259 ffective without the relatively high rate of adverse outcomes seen with invasive strategies.

260 sed exposure might translate to sex-specific adverse outcomes such as behavioral deficits is a possib

261 eported, as have possible increased risks of adverse outcomes such as ketoacidosis and bone fracture.

262 e lawsuits may be triggered by an unexpected adverse outcome superimposed on a strained patient-physi

263 better identify patients with severe OMR and adverse outcome than ECHO-derived integrative approach w

264 hemorrhage was more closely associated with adverse outcomes than microvascular obstruction.

265 ould identify patients at increased risk for adverse outcomes that are a consequence of acute kidney

266 ential route in linking chemical exposure to adverse outcomes that may reduce population sustainabili

267 Other adverse outcomes that occurred less frequently among inf

268 To equalize the occurrence of an adverse outcome, the proper listing MELD for patients wi

269 -specified, prospectively collected systemic adverse outcomes, the cumulative 7-year incidence in the

270 tion might also contribute to the genesis of adverse outcomes themselves.

271 ng acute heart failure (AHF) and can portend adverse outcomes; therefore, early identification may he

272 comes of interest were reduction of MTCT and adverse outcomes to mothers and newborns.

273 fying the minority of people at high risk of adverse outcomes, to allow intervention to slow CKD prog

274 nds, which may place them at greater risk of adverse outcomes under limiting conditions.

275 e the association between AF and in-hospital adverse outcomes using a large, prospective multicenter

276 rs of graft survival to minimize the risk of adverse outcomes was calculated.

277 No strong evidence of increased risk for adverse outcomes was found in comparisons of patients wh

278 Crohn's disease symptoms, the risk of major adverse outcomes was lower.

279 Included predictors for analysis of adverse outcome were diagnosis, age at start extracorpor

280 Hazard ratios for each adverse outcome were higher with higher quartiles of BNP

281 Multivariate independent predictors of adverse outcome were younger age at diagnosis, female se

282 Risk-adjusted adverse outcomes were 10.0 % in the best performing deci

283 Risk-adjusted adverse outcomes were 10.0 % in the best performing deci

284 fetal death were 7% in both groups; overall adverse outcomes were 46% among offspring of ZIKV-positi

285 Key adverse outcomes were bodyweight, homoeostatic model of

286 Adverse outcomes were chronic kidney disease, thyroid di

287 Adverse outcomes were defined as fetal loss or a live in

288 Adverse outcomes were frequent in those patients with pe

289 1999, the proportions of survivors reporting adverse outcomes were higher (P < 0.001) among those wit

290 Adjusted odds of adverse outcomes were higher in patients with CP for all

291 Adverse outcomes were more common among patients with po

292 n these two independent IPF cohorts, serious adverse outcomes were most frequent among the patients w

293 Adverse outcomes were noted regardless of the trimester

294 In contrast, adverse outcomes were observed in children who underwent

295 sociates with cell cycle gene expression and adverse outcome, whereas the number of mutations of sign

296 tation treatment with 101.10 abolished these adverse outcomes, whereas Kineret exerted only modest ef

297 chizophrenia might increase the liability to adverse outcomes with cannabis use is considered.

298 inical cutoffs were strongly associated with adverse outcomes with hazard ratios 8.8 (95% CI, 3.4-23.

299 Perforation was associated with adverse outcomes, with a legacy effect on later mortalit

300 , and facility-level factors associated with adverse outcomes within 7 days of ED discharge using log